Clinical Trial Update: A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007) [Phase 1]

View source ↗

Summary

Phase 1 multiple-dose titration study of MK-8892 in participants with pulmonary hypertension and left heart disease was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Left Heart Disease
• Pulmonary Hypertension

Drugs mentioned

• MK-8892 (MK-8892)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pulmonary Hypertension, Left Heart Disease | Phase 1 | Status: TERMINATED | Results posted: 2018-10-31